MultiCell Technologies Inc (MCET)

[PETERDENIEL2003]

Two strong reason to buy...

1.sponsored research agreement with University Health Network pursuant to which Anand Ghanekar, M.D., Ph.D., of the University Health Network's Toronto General Hospital, will direct research activities relating to the evaluation of MultiCell's product candidates MCT-465 and MCT-485, in in vitro models for the treatment of primary liver cancer.
http://www.trade4all.com/view_newsletters.php?email_id=32957&thetitle=PennyTrader+Midday+Report+for+July+11%2C+2011+SMHS%2C+DEGH%2C+MCET&desc=...


2. U.S. patent 7,935,528 by the United States Patent and Trademark Office (USPTO) relating to the isolation and use of human liver stem cells to treat liver disease. Under the terms of its license agreement with Rhode Island Hospital, MultiCell Technologies is the worldwide exclusive licensee of U.S. patent 7,935,528.
http://www.stockhaven.com/mcet-multicell-technologies-why-we-alerted-mcet-at-007-on-stem-cell-patent-news/